Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.86M | 66.41M | 74.68M | 43.69M | 64.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.86M | 66.41M | 74.68M | 43.69M | 64.60M |
| Cost of Revenue | 447.46M | 495.15M | 546.22M | 547.14M | 498.07M |
| Gross Profit | -392.60M | -428.74M | -471.54M | -503.45M | -433.47M |
| SG&A Expenses | 159.93M | 165.05M | 179.15M | 214.16M | 210.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 607.38M | 660.19M | 725.37M | 761.30M | 708.36M |
| Operating Income | -552.53M | -593.78M | -650.69M | -717.61M | -643.76M |
| Income Before Tax | -523.47M | -564.36M | -644.89M | -715.69M | -649.12M |
| Income Tax Expenses | -4.58M | -4.58M | -135.00K | -148.00K | 16.00K |
| Earnings from Continuing Operations | -518.88 | -559.78 | -644.76 | -715.54 | -649.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -518.88M | -559.78M | -644.76M | -715.54M | -649.13M |
| EBIT | -552.53M | -593.78M | -650.69M | -717.61M | -643.76M |
| EBITDA | -474.16M | -509.74M | -566.99M | -640.44M | -580.43M |
| EPS Basic | -1.04 | -1.20 | -1.48 | -1.81 | -1.79 |
| Normalized Basic EPS | -0.66 | -0.77 | -0.93 | -1.12 | -1.11 |
| EPS Diluted | -1.04 | -1.20 | -1.48 | -1.81 | -1.79 |
| Normalized Diluted EPS | -0.66 | -0.77 | -0.93 | -1.12 | -1.11 |
| Average Basic Shares Outstanding | 2.04B | 1.92B | 1.79B | 1.60B | 1.44B |
| Average Diluted Shares Outstanding | 2.04B | 1.92B | 1.79B | 1.60B | 1.44B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |